Xiao-guang LI, Ming-sheng LIU, Li-ying CUI. Clinical Phenotype Classification, Staging and Prognostic Evaluation of Amyotrophic Lateral Sclerosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 69-74. doi: 10.3969/j.issn.1674-9081.2018.01.013
Citation: Xiao-guang LI, Ming-sheng LIU, Li-ying CUI. Clinical Phenotype Classification, Staging and Prognostic Evaluation of Amyotrophic Lateral Sclerosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 69-74. doi: 10.3969/j.issn.1674-9081.2018.01.013

Clinical Phenotype Classification, Staging and Prognostic Evaluation of Amyotrophic Lateral Sclerosis

doi: 10.3969/j.issn.1674-9081.2018.01.013
More Information
  • Corresponding author: CUI Li-ying Tel:010-69156371, E-mail:pumchcuily@sina.com
  • Received Date: 2017-07-04
  • Publish Date: 2018-01-30
  • Amyotrophic lateral sclerosis(ALS) is a progressive neurodegenerative disease, characterized by insidious onset, slow progression, and death due to respiratory failure. There is no cure for it. Recent studies show that many measures can prolong the survival of patients with ALS, and improve their quality of life. In order to treat ALS scientifically and rationally, this paper introduces its clinical classification, staging, treatment mode, and methods for evaluating and following up the progress of ALS disease.
  • loading
  • [1] Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis[J]. N Engl J Med, 2017, 377:162-172. doi:  10.1056/NEJMra1603471
    [2] 李晓光, 崔丽英.肌萎缩侧索硬化手册[M].北京: 中国协和医科大学出版社, 2013: 294.
    [3] Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis[J]. J Neurol Sci, 1994, 124:96-107. doi:  10.1016/0022-510X(94)90191-0
    [4] Brooks BR, Miller RG, Swash M, et al. El Escorial revisited:revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Other Motor Neuron Disord, 2000, 5:293-299. https://reference.medscape.com/medline/abstract/11464847
    [5] de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS[J]. Clin Neurophysiol, 2008, 119:497-503. doi:  10.1016/j.clinph.2007.09.143
    [6] Chiò A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis:a population based study[J]. J Neurol Neurosurg Psychiatry, 2011, 82:740-746. doi:  10.1136/jnnp.2010.235952
    [7] Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis[J]. Brain, 2012, 135:847-852. doi:  10.1093/brain/awr351
    [8] Chiò A, Hammond ER, Mora G, et al. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2015, 86:38-44. doi:  10.1136/jnnp-2013-306589
    [9] Tramacere I, Dalla Bella E, Chiò A, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis[J]. J Neurol Neurosurg Psychiatry, 2015, 86:1180-1185. doi:  10.1136/jnnp-2014-310176
    [10] Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic lateral sclerosis[J]. Mayo Clin Proc, 1978, 53:173-178.
    [11] Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis(ALS)/motor neuron disease(MND)[J]. Cochrane Database Syst Rev, 2012, 3:CD001447. https://www.ncbi.nlm.nih.gov/pubmed/13129806/
    [12] Andersen PM, Abrahamsb S, Borasio D, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis(MALS)-revised report of an EFNS task force[J]. Eur J Neurol, 2012, 19:360-375. doi:  10.1111/j.1468-1331.2011.03501.x
    [13] Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update:The care of the patient with amyotrophic lateral sclerosis:drug, nutritional, and respiratory therapies(an evidence-based review):report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2009, 73:1218-1226. doi:  10.1212/WNL.0b013e3181bc0141
    [14] Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group[J].N Engl J Med, 1994, 330:585-591. doi:  10.1056/NEJM199403033300901
    [15] Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2011, 7:639-649. https://www.nature.com/articles/nrneurol.2011.153
    [16] Cedarbaum JM, Stambler N, Malta E, et al. The ALSFR-SR:a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group(Phase Ⅲ)[J]. J Neurol Sci, 1999, 169:13-21. doi:  10.1016/S0022-510X(99)00210-5
    [17] Maier A, Holm T, Wicks P, et al.Online assessment of ALS functional rating scale compares well to in-clinic evaluation:a prospective trial[J]. Amyotroph Lateral Scler, 2012, 13:210-216. doi:  10.3109/17482968.2011.633268
    [18] Küffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression[J]. Nat Biotechnol, 2015, 33:51-57. doi:  10.1038/nbt.3051
    [19] Jenkinson C, Levvy G, Fitzpatrick R, et al. The amyotrophic lateral sclerosis assessment questionnaire(ALSAQ-40):tests of data quality, score reliability and response rate in a survey of patients[J]. J Neurol Sci, 2000, 180:94-100. doi:  10.1016/S0022-510X(00)00420-2
    [20] Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2014, 10:661-670. doi:  10.1038/nrneurol.2014.184
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (412) PDF downloads(839) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return